US 12,632,231 · Application 18/461,064 · Granted May 19, 2026
US 12,632,231
Selecting layouts for user interfaces using free text
Estimated expiration
August 7, 2044
17y 301d remaining
Earliest effective filing
Sep 5, 2023
+ 20 years
Sep 5, 2043
PTA +337d
Aug 7, 2044
No TD
—
Final
Aug 7, 2044
This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included.
Calculation details
Base term
- Filing date
- September 5, 2023
- Earliest effective filing
- September 5, 2023
- Issue date
- May 19, 2026
- PTA
- +337 days
- Base expiry (before PTA)
- September 5, 2043
September 5, 2023 + 20 years = September 5, 2043 + 337 PTA days = August 7, 2044
- PRO63/405,417 — Provisional — not used for base term
- PRO63/426,748 — Provisional — not used for base term
- PRO63/436,639 — Provisional — not used for base term
- PRO63/439,080 — Provisional — not used for base term
- PRO63/441,097 — Provisional — not used for base term
- PRO63/444,841 — Provisional — not used for base term
- PRO63/534,747 — Provisional — not used for base term
Terminal disclaimers
Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated
The prosecution record for your AI
Application 18/461,064 · US 12,632,231
You have the date. Your AI can have the file.
PatentReply compiles the prosecution history behind US 12,632,231: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.
One new public application a month is free. The first compile takes a few minutes.
Strategy and filing changes require your approval.
Permanent link
www.patentreply.ai/tools/patent-expiration/US12632231Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.